Abstract:
Cancer treatment-induced cardiotoxicities are an ongoing concern throughout the cancer care continuum from treatment initiation to survivorship. Several ‘standard-of-care’ primary, secondary, and tertiary prevention strategies are available to prevent the development or further progression of cancer treatment-induced cardiotoxicities and their risk factors. Despite exercise’s established benefits on the cardiovascular system, it has not been widely adopted as a non-pharmacological cardioprotective strategy within cardio-oncology care. Within this State-of-the-Art Review we discuss cancer treatment-induced heart failure and coronary artery disease as two notable manifestations of cardiotoxicity with major health impacts, review the existing evidence supporting the role of exercise in preventing and managing these sequelae in at-risk and affected individuals living after a cancer diagnosis, and propose considerations for implementing exercise-based services in cardio-oncology practice.
JACC CardioOncology Editor-in-Chief and CME EditorBonnie Ky, MD, MSCE, FACCAuthorKelvin N.V. Bush, MD, FACC
Important Dates
Date of Release: October 17, 2023Term of Approval/Date of CME/MOC Expiration: October 16, 2024